Morgan Stanley Maintains Equal-Weight on Avery Dennison, Raises Price Target to $225

Morgan Stanley analyst Neel Kumar maintains Avery Dennison (NYSE:AVY) with a Equal-Weight and raises the price target from $215 to $225.

byBenzinga Newsdesk

August 2, 2021

1 minute read

Morgan Stanley analyst Neel Kumar maintains Avery Dennison (NYSE:AVY) with a Equal-Weight and raises the price target from $215 to $225.

Recap: SAP Q2 Earnings

By Benzinga Insights

Today, 8:39 AM

Shares of SAP (NYSE:SAP) decreased 4.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 63.57% over the past year to $2.11, which beat the estimate of $1.45.

SAP

Berenberg Downgrades bluebird bio to Hold, Announces $35 Price Target

By Benzinga Newsdesk

Today, 8:39 AM

Berenberg analyst Yun Zhong downgrades bluebird bio (NASDAQ:BLUE) from Buy to Hold and announces $35 price target.

BLUE

Mid-Day Market Update: Zoom Shares Drop After Q2 Results; AC Immune Shares Surge

By Lisa Levin

Today, 8:39 AM

Midway through trading Tuesday, the Dow traded down 0.01% to 35,396.15 while the NASDAQ fell 0.25% to 15,227.25. The S&P also fell, dropping 0.09% to 4,524.67.

ACIU

Catalyst Biosciences Q2 EPS $(0.64) Up From $(0.96) YoY, Sales $1.13M Down From $1.66M YoY

By Benzinga Newsdesk

Today, 8:39 AM

Catalyst Biosciences (NASDAQ:CBIO) reported quarterly losses of $(0.64) per share. This is a 33.33 percent increase over losses of $(0.96) per share from the same period last year. The company reported $1.13 million in

CBIO

Morgan Stanley Maintains Equal-Weight on Avery Dennison, Raises Price Target to $225

Related Posts

Recap: SAP Q2 Earnings

Berenberg Downgrades bluebird bio to Hold, Announces $35 Price Target

Mid-Day Market Update: Zoom Shares Drop After Q2 Results; AC Immune Shares Surge

Catalyst Biosciences Q2 EPS $(0.64) Up From $(0.96) YoY, Sales $1.13M Down From $1.66M YoY